Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of WAKAMOTO PHARMACEUTICAL CO.,LTD.. A complete text table follows the diagram.
Ethical-product revenue grew 41.8% to JPY2.20B, but OTC weakness and launch costs left operating income at a JPY196M loss.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Ethical products business-related | 1 | 2.2B | 50.3% of reported total |
| Otc products business-Related | 1 | 1.2B | 27.2% of reported total |
| Global Sales Development business-Related | 1 | 897M | 20.5% of reported total |
| Real estate leasing business | 1 | 92.3M | 2.1% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 4.4B | Reported six-month total · ¥4.4B |
| Operating loss | 2 | 196M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 4.6B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Ethical products business-related | Revenues From External Customers | 2.2B |
| Otc products business-Related | Revenues From External Customers | 1.2B |
| Global Sales Development business-Related | Revenues From External Customers | 897M |
| Real estate leasing business | Revenues From External Customers | 92.3M |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating costs & expenses | 4.4B |
| Operating loss | Operating costs & expenses | 196M |